RECURSION PHARMACEUTICALS, INC. Accumulated Other Comprehensive Income
RECURSION PHARMACEUTICALS, INC. (RXRX) had Accumulated Other Comprehensive Income of $27.99 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $27.99M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $26.66M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $36.72M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $34.09M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $27.99M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $26.66M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $36.72M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $34.09M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $43.62M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $14.14M 10-Q · filed 2025-05-05 |
| 2024-12-31 | -$7.64M 10-K · filed 2026-02-25 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-28 |
| 2022-12-31 | $0.00 10-K · filed 2023-02-27 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$197.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$309.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$126.00K 10-K · filed 2023-02-27 |
| 2021-09-30 | $2.00K 10-Q · filed 2021-11-10 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |